$DOCS

Sitaram Siddharth sold $44K of DOCS

Sitaram Siddharth (Chief Accounting Officer) sold 1,770 shares of Doximity, Inc. (DOCS) at $24.94 on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Aug 17, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

This is a disclosed open-market sale by a named officer, executed under a pre-arranged Rule 10b5-1 plan, with no other corporate event described.

02

Market read

Traders may log the transaction for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional news.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in compensation, or new company-specific catalysts.

Relevance 2/10Novelty 2/10Timing: Filed after-hours on 2026-08-17, reflecting a sale executed 2026-08-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Doximity, Inc. (DOCS).

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Doximity insider Form 4 shows Chief Accounting Officer Sitaram Siddharth sold 1,770 shares for about $44.1K under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory event.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with personal liquidity needs or risk management, which some traders may still monitor.

Key entities

  • Doximity, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sitaram Siddharth

    Chief Accounting Officer who sold 1,770 shares.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.